Albireo is developing novel bile acid modulators to treat rare pediatric and adult liver diseases. 


Bylvay™ (odevixibat) is approved for the treatment of pruritus in PFIC in the U.S. and for PFIC Europe. Elobixibat is approved for chronic constipation in Japan and Thailand. All other drugs and indications are currently investigational.